title: COMPARISONS BETWEEN THE NON-PROLIFERATIVE AND PROLIFERATIVE THERAPY IN FIBROCYSTIC MASTOSIS.
abstract: OBJECTIVE
  Fibrocystic mastosis (FCM) is the most frequent benign breast lesion. Most treatments for fibrocystic mastosis are: hormonl, with beneficial results and non-hormonal, with fluctuating results.
  
  
  METHODS
  A number of 210 cases were studied, which were divided into 7 groups. The study lasted for 9 months and it was carried out on the basis of a personal examination sheet. The following were monitored: age groups, mastodynia, reducing breast nodules, a significant reduction in the volume of the mastosic cysts, reducion of the fibrous tissue, medication tolerance.
  
  
  RESULTS
  Mastodynia has declined by 90% in the cases treated with Tamoxifen and Danazol, by 70% in the case of Lynestrenol and Bromocriptine, by 50% in the 15 patients who were given Utrogestan. Knowing the advantages and disadvantages of drugs (contraindications, side effects), age category, breast pain reduction, antiproliferative activity, tolerability, relapse allow us to assess the benefit-risk. Even in those circumstances that remained incompletely clarified for objective reasons, related to the inaccurate/incorrect reporting by the patients, there is a significant difference (p < 0.05) between the frequency of relapses following the treatment with Tamoxifen and the other categories of drugs who were administered.
  
  
  CONCLUSIONS
  Our study shows that in the groups that were administered Logest, Utrogestan and Bromocriptine, only antalgic effects were achieved (disappearance or only decrease of mastodynia) and no anti-proliferative effects were obtained. Basically, hormone treatment should be made based on a histopathological examination.
authors.forename: A
authors.initials: A
authors.lastname: Carauleanu
authors.forename: R
authors.initials: R
authors.lastname: Socolov
authors.forename: V
authors.initials: V
authors.lastname: Rugina
authors.forename: O
authors.initials: O
authors.lastname: Gabia
authors.forename: Daniela Mihaela
authors.initials: DM
authors.lastname: Carauleanu
authors.forename: Ivona Anghlcelache
authors.initials: IA
authors.lastname: Lupascu
authors.forename: Demetra
authors.initials: D
authors.lastname: Socolov
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001971:Bromocriptine / Q000627:therapeutic use; D003280:Contraceptives, Oral, Synthetic / Q000627:therapeutic use*; D003613:Danazol / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005348:Fibrocystic Breast Disease / Q000188:drug therapy* / Q000473:pathology; D005500:Follow-Up Studies; D006727:Hormone Antagonists / Q000627:therapeutic use*; D006801:Humans; D008234:Lynestrenol / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy; D012189:Retrospective Studies; D018570:Risk Assessment; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D003280:Contraceptives, Oral, Synthetic; D006727:Hormone Antagonists; D013629:Tamoxifen; D001971:Bromocriptine; D003613:Danazol; D008234:Lynestrenol